Specialty Pharmacy

Uptake of oral nucleoside/nucleotide analogues will increase from 2011 to 2021, according to new research from Decision Resources.

The Breakthrough Therapy initiative, which is part of the 2012 Food and Drug Administration Safety and Innovation Act, will bring promising treatments more quickly through an expedited review process.

Telik, Inc was recently notified that its product candidate, Telintra (ezatiostat HCL) has been granted orphan drug designation by theFDA for the treatment of myelodysplastic syndrome (MDS).

Professor Dusheiko talks about managing HCV patients with cirrhosis.

Here, UCSF's Annie Luetkemeyer talks about new treatments for hepatitis C and what they will do for people with infections.

FHI 360 President Emeritus Ward Cates discusses the HIV treatment cascade. This model aims to bring us closer to the end of AIDS by addressing the gaps in the HIV diagnosis and treatment system currently in place.

Arun K. Ghosh. professor of organic and medicinal chemistry at Purdue University, talks with Hiroaki Mitsuya, Head of Experimental Retrovirology Section at the National Cancer Institute, about HIV drug development.

Dr. Paul Richardson discusses promising drugs in the pipeline for the treatment of myeloma and new combination treatments using older drugs.

This video describes the use of targeted therapies for the treatment of multiple myeloma.

Landmark legislation requiring the National Cancer Institute to ramp up their research efforts on cancers with very low survival rates was signed into law early this month.

Stephen Vogt, PharmD, endeavors to create personalized treatment strategies for each patient.

National Association of Chain Drug Stores announced it has just added a "Developing Specialty Pharmacy" session to its program lineup for the 2013 Regional Chain Conference, which will take place February 3-5, 2013, in Fort Lauderdale, Florida.

Payers look to hepatitis C and do not see the value of credentialing bodies in specialty pharmacy, according to The Zitter Group's Fall 2012 Managed Care Biologics and Injectables Index.

Hospice Pharmacia (HP), a service of excelleRx, Inc, an Omnicare Specialty Care Group company and provider of medication management and pharmacy services, recently announced a new partnership with AccentCare, Inc, a leading multistate provider of hospice services.

Are corticosteroids still the number one drug for inducing clinical remission in IBD?

This is the first webcast series from the Crohn's & Colitis Foundation of America targeted to health care professionals.

Video from the National Multiple Sclerosis Society with the message, "MS Kills Connection. Connection Kills MS."

Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.

A new study revealed that lower doses of Velcade (bortezomib), melphalan (Alkeran) and prednisone (VMP) was effective and safe in extending overall and progression-free survival in older patients.

Representatives from The Dana –Farber Cancer Institute, Mount Sinai, and GNS Healthcare recently announced they are teaming up to pool their data and technology assets in order to build a predictive model of multiple myeloma disease progression.

This study discusses various treatments for multiple sclerosis, with a specific focus on alternative strategies like CCSVI.

This video summarizes the research findings from ECTRIMS 2012.

EMD Serono, Inc, a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced today that the FDA approved Rebif Rebidose (interferon beta-1a), a single-use auto-injector for the self-administration of Rebif, a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS).

Managed Health Care Associates, Inc (MHA), a leading health care service company focused on alternate site providers, is pleased to announce the acquisition of FMS Purchasing & Services, Inc and the Rebate Tracking Group (RTG) through its Navigator Group Purchasing subsidiary.

Looking for mobile apps relevant to your specialty business? Here are 7 recommendations from the editors of Specialty Pharmacy Times.

Clinical pathway programs in oncology will be utilized with more frequency in the coming years and may be instrumental in changing prescribing behavior, according to researchers from Decision Resources.

2 major HIV provider groups recently sent pharmaceutical companies and manufacturers a statement urging them to make their antiretrovirals more accessible to patients.

Adam J. Fein, PhD, discussed how wholesaler strategies must change in order to navigate an evolving drug channel infrastructure at the recent 8th Annual Trade and Channel Strategies Conference.

FDA granted accelerated approval to Iclusig (ponatinib) for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.